{"id":"NCT04673214","sponsor":"Gilberto Cruz Arteaga","briefTitle":"Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment","officialTitle":"Prognostic Modification in Patients With COVID-19 Under Early Intervention Treatment at U.M.F 13 and U.M.F 20","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-12-16","primaryCompletion":"2021-02-25","completion":"2021-02-25","firstPosted":"2020-12-17","resultsPosted":"2021-08-16","lastUpdate":"2021-08-16"},"enrollment":114,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Covid19"],"interventions":[{"type":"DRUG","name":"Azithromycin / Ivermectin / Ribaroxaban / Paracetamol","otherNames":["with Ivermectin"]},{"type":"DRUG","name":"Azithromycin / Ribaroxaban / Paracetamol","otherNames":["without Ivermectin"]}],"arms":[{"label":"Triple therapy","type":"EXPERIMENTAL"},{"label":"Double therapy","type":"ACTIVE_COMPARATOR"}],"summary":"The present study is designed for patients with mild COVID-19 phase, to demonstrate if there is a modification in the clinical evolution greater than or equal to 25% in their symptoms, implemented in two groups of patients under an early intervention treatment, a group ( A) will receive Azithromycin / Ivermectin / Ribaroxaban / Paracetamol and another group (B) will receive Azithromycin / Ribaroxaban / Paracetamol followed for 14 days followed by video call","primaryOutcome":{"measure":"Average Days in COVID-19 Symptoms by Type of Therapy in the UMF 20 and UMF 13 of the IMSS.","timeFrame":"14 days","effectByArm":[{"arm":"DOUBLE THERAPY","deltaMin":7,"sd":5.4},{"arm":"TRIPLE THERAPY","deltaMin":7,"sd":5.6}],"pValues":[{"comp":"OG000 vs OG001","p":"0.05"},{"comp":"OG000 vs OG001","p":"0.05"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":1},"locations":{"siteCount":1,"countries":["Mexico"]},"refs":{"pmids":["32205204","31818628","30786186","11841341","32322397","32438446"],"seeAlso":["https://doi.org/10.1016/j.ijantimicag.2020.105949","https://clinicaltrials.gov/ct2/show/results/NCT04343092?term=NCT04343092&draw=2&rank=1&view=results"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":46},"commonTop":["asthenia","Nausea","Tinnitus","Palpitations","Ecchymosis"]}}